Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Innovate Corp (VATE)

Innovate Corp (VATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,676
  • Shares Outstanding, K 13,655
  • Annual Sales, $ 1,107 M
  • Annual Income, $ -34,600 K
  • EBIT $ 34 M
  • EBITDA $ 75 M
  • 60-Month Beta 1.63
  • Price/Sales 0.04
  • Price/Cash Flow 8.91
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.75 +22.40%
on 03/23/26
5.29 -13.23%
on 03/03/26
-0.71 (-13.40%)
since 02/27/26
3-Month
3.75 +22.40%
on 03/23/26
5.99 -23.37%
on 02/04/26
-0.33 (-6.71%)
since 12/26/25
52-Week
3.75 +22.40%
on 03/23/26
8.52 -46.13%
on 03/28/25
-3.70 (-44.63%)
since 03/27/25

Most Recent Stories

More News
INNOVATE: Q4 Earnings Snapshot

INNOVATE: Q4 Earnings Snapshot

VATE : 4.59 (+13.90%)
INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches...

VATE : 4.59 (+13.90%)
INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full...

VATE : 4.59 (+13.90%)
Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN)

MediBeacon ® Transdermal GFR System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers began in...

VATE : 4.59 (+13.90%)
INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully...

VATE : 4.59 (+13.90%)
DBM Global to Pay Cash Dividend

PHOENIX, Jan. 30, 2026 (GLOBE NEWSWIRE) -- DBM Global Inc. (“DBMG”), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE Corp. (NYSE:...

VATE : 4.59 (+13.90%)
DBMG : 75.0000 (+7.14%)
MediBeacon® Next Generation TGFR™ System Receives FDA Approval

MediBeacon ® TGFR TM System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers begins in early...

VATE : 4.59 (+13.90%)
INNOVATE: Q3 Earnings Snapshot

INNOVATE: Q3 Earnings Snapshot

VATE : 4.59 (+13.90%)
INNOVATE Corp. Announces Third Quarter 2025 Results

- Infrastructure: DBM Global delivers robust revenue growth, reinforcing market leadership - - Life Sciences: MediBeacon received regulatory approval to sell the Transdermal GFR System in China - ...

VATE : 4.59 (+13.90%)
INNOVATE Corp. to Report Third Quarter 2025 Results on November 12th

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2025 on...

VATE : 4.59 (+13.90%)

Business Summary

INNOVATE Corp. is a portfolio of assets in areas of infrastructure, life sciences and spectrum. INNOVATE Corp., formerly known as HC2 Holdings Inc., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 5.75
2nd Resistance Point 5.31
1st Resistance Point 4.95
Last Price 4.59
1st Support Level 4.14
2nd Support Level 3.70
3rd Support Level 3.34

See More

52-Week High 8.52
Fibonacci 61.8% 6.70
Fibonacci 50% 6.14
Fibonacci 38.2% 5.57
Last Price 4.59
52-Week Low 3.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.